Significant efforts are underway to align U.S. drug prices with lower international rates.
A significant portion of these companies is owned by large institutional investors like Blackrock, Vanguard, and State Street, which collectively hold roughly 20% of the industry. Big Pharma
Key drugs driving recent revenue include semaglutide (Ozempic/Wegovy) from Novo Nordisk and various high-cost therapies for chronic conditions. Current Pricing and Regulatory Trends Significant efforts are underway to align U
Eli Lilly, Johnson & Johnson, AbbVie, and Roche are among the largest global players. and State Street